ResApp

The UK-based wearable medical device company plans to use the funds to expand in Europe and North America.

Also, a new research centre at the University of Melbourne will use AI to advance breast cancer screening.

Also, annalise.ai has made key executive appointments to support its global expansion.

It has been approved as a prescription-only software-as-a-medical device in the US.

The proposed acquisition and research partnership will add​​ to the biopharmaceutical giant's growing digital capabilities and bolster its efforts "to pave a new era for digital health".

The app has correctly detected COVID-19 in 92% of infected participants of a clinical trial.

The feature will be introduced in the second quarter of the year.

Brisbane-based digital health company, ResApp Health has announced the launch of SleepCheck, a mobile medical device software application that analyses a user’s breathing and snoring sounds during sleep and provides an assessment of their risk of sleep apnoea.

The app requires no accessories or hardware other than the user’s smartphone.  

The news follows after the company’s ResAppDx-EU version 2 smartphone app was approved by the Australian TGA as a Class IIa medical device.